Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First in Human Phase 1 Dose Escalation and Expansion Clinical Trial to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of Intravenous AROG4-01 in Patients With Advanced Solid Tumors

NCT06652529 is registered in ClinicalTrials.gov with Aromics Therapeutics as lead sponsor.

NCT NCT06652529
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06652529 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First in Human Phase 1 Dose Escalation and Expansion Clinical Trial to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of Intravenous AROG4-01 in Patients With Advanced Solid Tumors
Lead sponsor
Aromics Therapeutics
Phase
Phase 1
Overall status
Not yet recruiting
Start date
January 31, 2025
Completion date
December 31, 2026
Enrollment
35 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal carcinoma, mesothelioma, nsclc (advanced non-small cell lung cancer), ovarian cancer, solid tumors (phase 1)